In conclusion, the present study has demonstrated the potential of BZYQ in alleviating paclitaxel chemotherapy-related fatigue by reducing the serum level of TNF-α and modulating the levels of MDA and SOD activity in the 4 T1 murine breast cancer model. This evidence concerns the gene SOD1 and breast cancer.